A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Inclusion Criteria: * Diagnosis of Type 2 diabetes mellitus in accordance with American Diabetes Association guidelines * Have Stage 3 chronic kidney disease * On stable diabetes therapy (diet/exercise therapy alone or anti-hyperglycemic agents \[AHA\] monotherapy or combination therapy) for at least 6 weeks prior to study participation OR on metformin (with or without diet/exercise therapy or other AHA therapy) and is willing to undergo a 10-week metformin wash-off period * Have an estimated glomerular filtration rate (eGFR) of ≥30 to \<60 mL/min/1.73m\^2 * Body Mass Index (BMI) greater than or equal to 18.0 kg/m\^2 * Male, postmenopausal female or surgically sterile female * If a female of reproductive potential, agrees to remain abstinent or to use (or have their partner use) 2 acceptable combinations of birth control while participating in the trial and for 14 days after the last use of study drug. Exclusion Criteria: * History of type 1 diabetes mellitus or a history of ketoacidosis * History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug - or chemical-induced, and post-organ transplant) * History of nephrotic range proteinuria with hypoalbuminemia and edema * History of rapidly progressive glomerulonephritis, lupus nephritis, renal or systemic vasculitis, renal artery stenosis with renovascular hypertension, or ischemic nephropathy * History of familial renal glucosuria * History of renal dialysis or renal transplant or renal disease requiring treatment with any immunosuppressive agent * A known hypersensitivity or intolerance to any (sodium-glucose co-transporter 2) SGLT2 inhibitor * On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable * Has undergone bariatric surgery within the past 12 months * Has been treated with rosiglitazone or other SGLT2 inhibitors within 12 weeks of study participation * Has active, obstructive uropathy or indwelling urinary catheter * History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation * A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer * Known history of Human Immunodeficiency Virus (HIV) * Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other clinically significant hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) * A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease * Has any clinically significant malabsorption condition * If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation * Has been previously randomized in a study with ertugliflozin * Has participated in other studies involving an investigational drug within 30 days prior or during study participation * Has undergone a surgical procedure within 6 weeks prior to or during study participation * Has a positive urine pregnancy test * Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication * Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication * Excessive consumption of alcoholic beverages or binge drinking * Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial